Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
Clinical trial NCT04582864 · TERMINATED
Trial details
- NCT number
- NCT04582864
- Sponsor
- Washington University School of Medicine
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-20
- Primary completion
- 2024-03-29
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.